Our delivery platform is our research and development (R&D) cornerstone — a robust and scalable engine for delivering therapeutic agents that activate and direct immune responses in a controlled, impactful way. Our R&D teams are able to leverage the unique mechanism of action of our platform to impact the way we harness the immune system in the fight against cancer and other serious diseases.
Our R&D strategy focuses on developing our own immuno-oncology product candidates with our partners. We are focused on areas in immuno-oncology where we can drive most value in expanding the range of patient populations responsive to recent advances in immunotherapies, particularly in hard-to-treat cancers that include advanced ovarian cancer.
Because our platform is widely applicable to many therapeutic markets, we are also investigating opportunities to out-license our technology with partners in other treatment areas.